| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Emily Luisa Hill | CFO | 2026-08-17 | 9,256 | $14.28 | $132.18kSell |
| Andrew Schwendenman | CAO | 2026-08-10 | 7,632 | $12.97 | $98.99kSell |
| Sushil Patel | CEO | 2026-08-10 | 39,341 | $12.97 | $510.25kSell |
| Konstantinos Xynos | Med | 2026-08-10 | 11,447 | $12.97 | $148.47kSell |
| Emily Luisa Hill | CFO | 2026-08-10 | 11,448 | $12.97 | $148.48kSell |
| Christopher Sarchi | Chief Commercial Officer | 2026-06-01 | 12,000 | $9.24 | $110.88kSell |
| Philip Astleysparke | Director | 2026-05-18 | 17,657 | $5.08 | $89.70kSell |
| Emily Luisa Hill | Chief Financial Officer | 2026-05-18 | 7,812 | $5.08 | $39.68kSell |
| Sushil Patel | Chief Executive Officer | 2026-05-18 | 37,324 | $5.08 | $189.61kSell |
| Christopher Sarchi | Chief Commercial Officer | 2026-05-18 | 8,626 | $5.08 | $43.82kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Baker Bros Advisors LP | 10.67% | 10,116,095 | $175.92M | Insider |
| Omega Fund IV LP | 9.95% | 9,436,760 | $164.11M | Insider |
| Hugo Alexander Slootweg | 4.98% | 4,721,449 | $82.11M | Insider |
| Forbion Capital Fund III Cooperatief Ua | 4.98% | 4,721,449 | $82.11M | Insider |
| Bain Capital Life Sciences Investors LLC | 2.99% | 2,838,968 | $49.37M | Insider |
| Atlas Venture Fund X LP | 2.62% | 2,486,296 | $43.24M | Insider |
| Robert Coffin | 1.92% | 1,821,872 | $31.68M | Insider |
| Philip Astleysparke | 1.44% | 1,362,414 | $23.69M | Insider |
| Atlas Venture Opportunity Fund I LP | 1.16% | 1,100,000 | $19.13M | Insider |
| Redmile Group LLC | 0.82% | 779,655 | $13.56M | Insider |